Press release
Systemic Sclerosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight
Systemic Sclerosis Clinical Trials
Request a sample and discover the recent advances in Systemic Sclerosis Treatment Drugs @ Systemic Sclerosis Pipeline Report- https://www.delveinsight.com/report-store/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Systemic Sclerosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key Takeaways from the Systemic Sclerosis Pipeline Report
• DelveInsight's Systemic Sclerosis pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Systemic Sclerosis treatment.
• Leading Systemic Sclerosis companies working in the Market include Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Pfizer, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences, and others.
• Promising Systemic Sclerosis Pipeline Therapies in the various stages of development include GS-248, KHK4827, Paquinimod, Inebilizumab, Nemolizumab, RO7303509, Treprostinil Diethanolamine, and others.
• On September 2023, Horizon Pharma Ltd announced a study of phase 2 clinical trials for HZN-825 BID. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension trial will participate in a Safety Follow-up Visit 4 weeks after the last dose of trial drug.
• On September 2023, Hospital for Special Surgery, New York announced a study of phase 2 clinical trials for Belimumab, and MMF. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab & Rituximab or placebo. Patients in both groups will be on background MMF for the entirety of the study. Belimumab will be administered subcutaneously and Rituximab intravenously.
Systemic Sclerosis Overview
Scleroderma, also known as Systemic Sclerosis, progressive systemic sclerosis or the CREST syndrome, is a chronic skin disorder that affects the skin, connective tissues and other internal organs. The disorder takes place sin humans, when the immune system causes the body to make the protein collagen, an important component of the skin, in huge amounts.
Find out more about Systemic Sclerosis Therapeutics Assessment @ Systemic Sclerosis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Systemic Sclerosis Emerging Drugs Profile
• Iloprost: Eicos Sciences
• ECCS 50: Cytori therapeutics
• Lenabasum (JBT-101): Corbus Pharmaceuticals
• EHP-101: Emerald Health Pharmaceuticals
Systemic Sclerosis Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the Systemic Sclerosis therapies. The Systemic Sclerosis companies which have their Systemic Sclerosis drug candidates in the most advanced stage, i.e. Phase III include, Eicos Sciences.
Learn more about the emerging Systemic Sclerosis Pipeline Therapies @ Systemic Sclerosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Systemic Sclerosis Pipeline Report
• Coverage- Global
• Systemic Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Systemic Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Systemic Sclerosis Companies- Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Pfizer, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences, and others.
• Systemic Sclerosis Pipeline Therapies- GS-248, KHK4827, Paquinimod, Inebilizumab, Nemolizumab, RO7303509, Treprostinil Diethanolamine, and others.
Dive deep into rich insights for new drugs for Systemic Sclerosis Treatment Market, Visit @ Systemic Sclerosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Systemic Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Iloprost: Eicos Sciences
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. EHP-101: Emerald Health Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. VIB7734: Viela Bio
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Systemic Sclerosis Key Companies
17. Systemic Sclerosis Key Products
18. Systemic Sclerosis- Unmet Needs
19. Systemic Sclerosis- Market Drivers and Barriers
20. Systemic Sclerosis- Future Perspectives and Conclusion
21. Systemic Sclerosis Analyst Views
22. Systemic Sclerosis Key Companies
23. Appendix
For further information on the Systemic Sclerosis pipeline therapeutics, reach out to Systemic Sclerosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-rhino-conjunctivitis-market
• Sialidosis Market: https://www.delveinsight.com/report-store/sialidosis-market
• Stable Angina Market: https://www.delveinsight.com/report-store/stable-angina-market
• Thymic Carcinoma Market: https://www.delveinsight.com/report-store/thymus-cancer-market
• Turner Syndrome Market: https://www.delveinsight.com/report-store/turner-syndrome-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/ventricular-fibrillation-market
• Waiha Market: https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market
• Wegener S Granulomatosis/granulomatosis With Polyangiitis Market: https://www.delveinsight.com/report-store/wegeners-granulomatosis-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Systemic Sclerosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight here
News-ID: 3798313 • Views: …
More Releases from DelveInsight Business Research
Biliary Tract Cancer Market: Growth Momentum Across 7MM to 2034 - DelveInsight
DelveInsight's "Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Biliary Tract Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Tract Cancer…
Behcet's Disease Market: Expanding Revenue Landscape to 2034 - DelveInsight
DelveInsight's "Behcet's Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Behcet's Disease, historical and forecasted epidemiology as well as the Behcet's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Behcet's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Behcet's Disease Market Forecast
https://www.delveinsight.com/sample-request/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Anaphylaxis Market: Rapid Increment Driven by Innovation - DelveInsight
DelveInsight's "Anaphylaxis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Anaphylaxis, historical and forecasted epidemiology as well as the Anaphylaxis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Anaphylaxis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Anaphylaxis Market Forecast
https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Anaphylaxis…
Tendonitis Market: Strong Pharma Growth Forecast Through 2034 - DelveInsight
The Tendonitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tendonitis pipeline products will significantly revolutionize the Tendonitis market dynamics.
DelveInsight's "Tendonitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Tendonitis, historical and forecasted epidemiology as well as the Tendonitis market trends in the United States, EU5 (Germany, Spain, Italy, France,…
More Releases for Systemic
What Is Driving Global Systemic Aspergillosis And Systemic Candidiasis Market Gr …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Systemic Aspergillosis And Systemic Candidiasis Market Size Growth Forecast: What to Expect by 2025?
The market valuation for systemic aspergillosis and systemic candidiasis has experienced consistent upward momentum across recent years, projected to advance from a figure of $7.24 billion in 2024 to reach $7.57 billion by 2025, reflecting…
Transformative Trends Impacting the Systemic Aspergillosis And Systemic Candidia …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Systemic Aspergillosis And Systemic Candidiasis Market Size By 2025?
The growth trend of the systemic aspergillosis and systemic candidiasis market has been steadily ascending in the past few years. The market size will inflate from $7.24 billion in 2024 to $7.59 billion in 2025, indicating…
Systemic Aspergillosis And Systemic Candidasis Market Size by Type, Application, …
According to Market Research Intellect, the global Systemic Aspergillosis And Systemic Candidasis market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The growing prevalence of invasive fungal infections, especially in immunocompromised persons, is propelling the global…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market - Industry Over …
The systemic aspergillosis and systemic candidiasis treatment market is gaining significant attention within the global healthcare and pharmaceutical industries due to the increasing incidence of life-threatening fungal infections among immunocompromised individuals. Both systemic aspergillosis and systemic candidiasis are opportunistic fungal infections, often affecting patients with weakened immune systems due to cancer therapy, organ transplantation, HIV/AIDS, or intensive care treatments.
The systemic aspergillosis and systemic candidiasis treatment market was valued at approximately…
Systemic Aspergillosis and Systemic Candidiasis Market Share, Sales Channels and …
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The systemic aspergillos is and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019. The market is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
To get sample Copy of the report, along with…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market Insight & Futur …
(Portland, United States): Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Systemic Aspergillosis and Systemic Candidiasis Treatment Market in the latest research report added by Big Market Research. The recent research report on the global Systemic Aspergillosis and Systemic Candidiasis Treatment Market presents the latest industry data and future trends, allowing you to recognize the products and end…
